MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
10 avr. 2021 08h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
26 févr. 2021 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
25 févr. 2021 16h01 HE
|
MacroGenics, Inc.
MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
18 févr. 2021 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Names Federica O’Brien to its Board of Directors
11 févr. 2021 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
11 févr. 2021 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
08 févr. 2021 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
25 janv. 2021 07h30 HE
|
MacroGenics, Inc.
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...
MacroGenics to Participate in Upcoming Investor Conferences
11 janv. 2021 08h45 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
22 déc. 2020 11h35 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...